Use of specific indicators to detect warfarin-related adverse events

American Journal of Health-System Pharmacy

Volumn 62, Issue 16, 2005, Pages 1683-1688

  Hartis, Charles E ^a   Gum, Michael O ^b   Lederer Jr , James W ^c  

^a FORSYTH MEDICAL CENTER   (United States)

^b PRESBYTERIAN HOSPITAL   (United States)

^c Novant Health   (United States)

Author keywords

Anticoagulants; Dosage; Education; Health professions; International Normalized Ratio; Phytonadione; Toxicity; Vitamins; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; PHYTOMENADIONE; VITAMIN K GROUP; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COMMUNITY HOSPITAL; DRUG DOSE REGIMEN; DRUG MONITORING; EMERGENCY WARD; HEMATOLOGICAL PARAMETERS; HOSPITAL PERSONNEL; HOSPITAL PHARMACY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MAJOR CLINICAL STUDY; NURSE; PATIENT MONITORING; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 23844495198     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040404     Document Type: Article

References (22)

1. Brennan TA, Leape LL, Laird NM et al. Incidence of adverse events and negligence in hospitalized patients. Results of the Harvard Medical Practice Study I. N Engl J Med. 1991; 324:370-6.
2. Leape LL, Brennan TA, Laird NM et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
3. Thomas EJ, Studdert DM, Burstin HR et al. Incidence and types of adverse events and negligent care in Utah and Colorado. Med Care. 2000; 38:261-71.
4. Kanjanarat P, Winterstein AG, John TE et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health-Syst Pharm. 2003; 60:1750-9.
5. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: National Academy Press; 1999.
6. Leape LL, Bates DW, Cullen DJ et al. Systems analysis of adverse drug events. JAMA. 1995; 274:35-43.
7. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997; 277:301-6.
8. Classen DC, Pestotnik SL, Evans RS et al. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991; 266:2847-51.
9. Monitoring adverse drug events: finding needles in the haystack. Irving, TX: VHA; 2002.
10. Classen DC, Pestotnik SL, Evans RS et al. Description of a computerized adverse drug event monitor using a hospital information system. Hosp Pharm. 1992; 27:774,776-9.
11. Evans RS, Pestotnik SL, Classen DC et al. Preventing adverse drug events in hospitalized patients. Ann Pharmacother. 1994; 28:523-7.
12. National Coordinating Council for Medication Error Reporting and Prevention. Taxonomy of medication errors. www. nccmerp.org/pdf/taxo2001-07-31. pdf. (accessed 2004 Jul 12).
13. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
14. Resar RK, Rozich JD, Classen DC. Methodology and rationale for the measurement of harm with trigger tools. Qual Saf Health Care. 2003; 12:39-45.
15. Rozich JD, Haraden CR, Resar RK. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. Qual Saf Health Care. 2003; 12:194-200.
16. Kucukarslan SN, Peters M, Mlynarek M et al. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003; 163:2014-8.
17. Roberts GW, Druskeit T, Jorgensen LE et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust N Z J Med. 1999; 29:731-6.
18. Crowther MA, Ginsberg JB, Kearon C et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med. 1999; 159:46-8.
19. Wells PS, Holbrook AM, Crowther NR et al. Interactions of warfarin with drugs and food. Ann Intern Med. 1994; 121:676-83.
20. Weibert RT, Le DT, Kayser SR et al. Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med. 1997; 125:959-62.
21. Becker RC, Ansell J. Antithrombotic therapy. An abbreviated reference for clinicians. Arch Intern Med. 1995; 155:149-61.
22. Hirsh J, Dalen J, Guyatt G et al. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. Chest. 2001; 119(1, suppl):1s-2s.